CancerDrs

Leukemia clinical trials in Tennessee

39 actively recruiting leukemia trials at 7 sites across Tennessee.

Data from ClinicalTrials.gov · last refreshed

Payments from drug makers to the doctors running these trials

For 1 of the trials on this page, the pharmaceutical company funding the trial also disclosed payments to the physicians leading it — public data from the federal CMS Open Payments database. Paying clinical-trial investigators for site work is expected and necessary for industry-funded trials; the scale and source are simply useful context when you're deciding whether to enroll. See the full leukemia transparency page →

Phase 3 Recruiting NIH

Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

This phase III trial compares early treatment with venetoclax and obinutuzumab versus delayed treatment with venetoclax and obinutuzumab in patients with newly diagnosed high-risk chronic lymphocytic leukemia or small lymphocytic lymphoma.…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04269902
Sites in Tennessee:
  • Bristol Regional Medical Center — Bristol, Tennessee
  • Baptist Memorial Hospital and Cancer Center-Collierville — Collierville, Tennessee
  • Ballad Health Cancer Care - Kingsport — Kingsport, Tennessee
  • Wellmont Holston Valley Hospital and Medical Center — Kingsport, Tennessee
  • Baptist Memorial Hospital and Cancer Center-Memphis — Memphis, Tennessee
View on ClinicalTrials.gov →
Phase 3 Recruiting Network

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

This phase III trial compares standard chemotherapy to therapy with liposome-encapsulated daunorubicin-cytarabine (CPX-351) and/or gilteritinib for patients with newly diagnosed acute myeloid leukemia with or without FLT3 mutations. Drugs …

Sponsor: Children's Oncology Group
NCT ID: NCT04293562
Sites in Tennessee:
  • T C Thompson Children's Hospital — Chattanooga, Tennessee
  • East Tennessee Childrens Hospital — Knoxville, Tennessee
  • The Children's Hospital at TriStar Centennial — Nashville, Tennessee
  • Vanderbilt University/Ingram Cancer Center — Nashville, Tennessee
View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL

This phase III trial compares the effect of adding sonrotoclax to zanubrutinib versus zanubrutinib alone for the treatment of patients with untreated chronic lymphoblastic leukemia (CLL)/small lymphocytic lymphoma (SLL). Sonrotoclax is in …

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT07321652
Sites in Tennessee:
  • Baptist Memorial Hospital and Cancer Center-Collierville — Collierville, Tennessee
  • Baptist Memorial Hospital and Cancer Center-Memphis — Memphis, Tennessee
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

The purpose of this study is to assess how bleximenib and Venetoclax (VEN)+ Azacitidine (AZA) works as compared to placebo and VEN+AZA alone for the treatment of participants with newly diagnosed Acute Myeloid Leukemia (AML) with a mutatio…

Sponsor: Janssen Research & Development, LLC
NCT ID: NCT06852222
Sites in Tennessee:
  • University of Tennessee — Knoxville, Tennessee
  • Vanderbilt Ingram Cancer Center — Nashville, Tennessee
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)

The goal of this study is to evaluate nemtabrutinib compared with investigator's choice of ibrutinib or acalabrutinib in participants with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who have not received any prior …

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06136559
Sites in Tennessee:
  • Tennessee Oncology-Chattanooga ( Site 0045) — Chattanooga, Tennessee
  • Tennessee Oncology, PLLC - Elliston Place Plaza Medical Oncology & Hematology ( Site 0031) — Nashville, Tennessee
View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)

A study to evaluate if the randomized addition of venetoclax to a chemotherapy backbone (fludarabine/cytarabine/gemtuzumab ozogamicin \[GO\]) improves survival of children/adolescents/young adults with acute myeloid leukemia (AML) in 1st r…

Sponsor: PedAL BCU, LLC
NCT ID: NCT05183035
Sites in Tennessee:
  • St. Jude Children's Research Hospital — Memphis, Tennessee
  • Monroe Carell Jr. Children's Hospital at Vanderbilt — Nashville, Tennessee
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

Ziftomenib is an investigational drug in development for the treatment of patients with acute myeloid leukemia (AML) with eligible genetic alterations. Ziftomenib is a type of therapy known to target the menin pathway in cancer cells. This…

Sponsor: Kura Oncology, Inc.
NCT ID: NCT07007312
Sites in Tennessee:
  • Baptist Clinical Research Institute — Memphis, Tennessee
  • Tennessee Oncology — Nashville, Tennessee
  • TriStar Centennial Medical Center — Nashville, Tennessee
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)

The goal of this study is to compare how well sonrotoclax plus obinutuzumab works versus venetoclax plus rituximab in treating adults with relapsed and/or refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). …

Sponsor: BeOne Medicines
NCT ID: NCT06943872
Sites in Tennessee:
  • Tennessee Oncology Greco Hainsworth Centers For Research Chattanooga — Chattanooga, Tennessee
  • Tennessee Oncology — Nashville, Tennessee
View on ClinicalTrials.gov →
Phase 3 Recruiting Network

Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia

This phase III trial compares the effect of xylitol dental wipes to dental wipes without xylitol for the reduction of bloodstream infection in children with acute myeloid leukemia (AML). Xylitol is a naturally occurring sugar compound foun…

Sponsor: Children's Oncology Group
NCT ID: NCT07022678
Sites in Tennessee:
  • East Tennessee Childrens Hospital — Knoxville, Tennessee
  • The Children's Hospital at TriStar Centennial — Nashville, Tennessee
View on ClinicalTrials.gov →
Phase 2, Phase 3 Recruiting Industry

A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)

Study ASTX030-01 is a multi-phase study comprising of Phases 1-3 Monotherapy arms, and Phase 1 and Phase 2 Combination Therapy arms. Phase 1 Monotherapy consists of an open-label Dose Escalation Stage (Stage A) using multiple cohorts at es…

Sponsor: Taiho Oncology, Inc.
NCT ID: NCT04256317
Sites in Tennessee:
  • Vanderbilt University Medical Center — Nashville, Tennessee
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

The purpose of Part 1 of this study is to compare the efficacy and safety of pirtobruitinib (LOXO-305) to ibrutinib in participants with CLL/SLL; participants may or may not have already had treatment for their cancer. The purpose of Part …

Sponsor: Loxo Oncology, Inc.
NCT ID: NCT05254743
Sites in Tennessee:
  • Sarah Cannon Research Institute SCRI — Nashville, Tennessee
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

This MyeloMATCH Master Screening and Reassessment Protocol (MSRP) evaluates the use of a screening tool and specific laboratory tests to help improve participants' ability to register to clinical trials throughout the course of their myelo…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05564390
Sites in Tennessee:
  • Baptist Memorial Hospital and Cancer Center-Collierville — Collierville, Tennessee
  • University of Tennessee - Knoxville — Knoxville, Tennessee
  • Baptist Memorial Hospital and Cancer Center-Memphis — Memphis, Tennessee
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

This phase II MyeloMATCH treatment trial compares the usual treatment of azacitidine and venetoclax to the combination treatment of azacitidine, venetoclax and gilteritinib in treating older and unfit patients with acute myeloid leukemia a…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06317649
Sites in Tennessee:
  • Baptist Memorial Hospital and Cancer Center-Collierville — Collierville, Tennessee
  • University of Tennessee - Knoxville — Knoxville, Tennessee
  • Baptist Memorial Hospital and Cancer Center-Memphis — Memphis, Tennessee
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

This phase II trial studies the effect of nivolumab in combination with blinatumomab compared to blinatumomab alone in treating patients with B-cell acute lymphoblastic leukemia (B-ALL) that has come back (relapsed). Down syndrome patients…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04546399
Sites in Tennessee:
  • East Tennessee Childrens Hospital — Knoxville, Tennessee
  • The Children's Hospital at TriStar Centennial — Nashville, Tennessee
  • Vanderbilt University/Ingram Cancer Center — Nashville, Tennessee
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

This phase II MyeloMATCH treatment trial compares cytarabine with daunorubicin versus cytarabine with daunorubicin and venetoclax versus venetoclax with azacitidine for the treatment of younger patients with intermediate risk acute myeloid…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05554393
Sites in Tennessee:
  • Baptist Memorial Hospital and Cancer Center-Collierville — Collierville, Tennessee
  • Baptist Memorial Hospital and Cancer Center-Memphis — Memphis, Tennessee
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin, "7+3") for Core Binding Factor Acute Myeloid Leukemia (CBF-AML) to Improve Response (A MYELOMATCH Treatment Trial)

This phase II MYELOMATCH treatment trial compares the effect of venetoclax to gemtuzumab ozogamicin, when given with cytarabine and daunorubicin ("7+3" regimen), for the treatment of patients with core binding factor acute myeloid leukemia…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06917911
Sites in Tennessee:
  • Baptist Memorial Hospital and Cancer Center-Collierville — Collierville, Tennessee
  • Baptist Memorial Hospital and Cancer Center-Memphis — Memphis, Tennessee
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies

Study consists of two main parts to explore BGB-16673 recommended dosing, a Phase 1 monotherapy dose finding comprised of monotherapy dose escalation and monotherapy safety expansion of selected doses, and a Phase 2 (expansion cohorts)

Sponsor: BeOne Medicines
NCT ID: NCT05006716
Sites in Tennessee:
  • Tennesse Oncology Chattanooga Downtown — Chattanooga, Tennessee
  • Tennessee Oncology, Pllc Nashville — Nashville, Tennessee
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Academic/Other

A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia

This clinical trial will test the safety and efficacy of combining trametinib and azacitidine in patients with juvenile myelomonocytic leukemia (JMML). Newly diagnosed lower-risk JMML patients will receive trametinib and azacitidine. High-…

Sponsor: Therapeutic Advances in Childhood Leukemia Consortium
NCT ID: NCT05849662
Sites in Tennessee:
  • St. Jude Children's Research Hospital Memphis — Memphis, Tennessee
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

This study will evaluate the safety, tolerability, and efficacy of Orca-T in participants undergoing reduced intensity or non-myeloablative allogeneic hematopoietic cell transplantation (alloHCT) for hematologic malignancies. Orca-T is an …

Sponsor: Orca Biosystems, Inc.
NCT ID: NCT07216443
Sites in Tennessee:
  • Vanderbilt University, Ingram Cancer Center — Nashville, Tennessee
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)

This is a clinical trial testing whether the addition of one of two chemotherapy agents, dasatinib or venetoclax, can improve outcomes for children and young adults with newly diagnosed T-cell acute lymphoblastic leukemia and lymphoma or m…

Sponsor: St. Jude Children's Research Hospital
NCT ID: NCT06390319
Sites in Tennessee:
  • St. Jude Children's Research Hospital — Memphis, Tennessee
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Academic/Other

Study of CM4620 to Reduce the Severity of Pancreatitis Due to Asparaginase

This is a phase I/II clinical trial assessing the tolerability and efficacy of CM4620 in children and young adults with acute pancreatitis caused by asparaginase. The tolerability of CM4620 when given to patients receiving frontline chemot…

Sponsor: St. Jude Children's Research Hospital
NCT ID: NCT04195347
Sites in Tennessee:
  • St. Jude Children's Research Hospital — Memphis, Tennessee
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

Exercise Training and NR Supplementation Trial to Improve Fitness in AYA HCT Survivors

This will be a randomized, placebo-controlled trial with a 2x2 factorial design testing the effects of an NAD+ precursor (NR) and exercise on skeletal muscle quality and VO2max in AYA HCT survivors. The primary outcome is the change in mus…

Sponsor: Children's Hospital of Philadelphia
NCT ID: NCT05194397
Sites in Tennessee:
  • St. Jude Children's Research Hospital — Memphis, Tennessee
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

Therapy for Newly Diagnosed Patients With B-Cell Precursor Acute Lymphoblastic Leukemia and Lymphoma

This is a Phase II clinical trial testing the use of two antigen-directed therapies, inotuzumab and blinatumomab, as part of induction therapy for children and young adults with newly diagnosed B-cell precursor acute lymphoblastic leukemia…

Sponsor: St. Jude Children's Research Hospital
NCT ID: NCT06533748
Sites in Tennessee:
  • St. Jude Children's Research Hospital — Memphis, Tennessee
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

CAR T CELL Therapy for Pediatric, Adolescent and Young Adult Patients With CD19-Positive Leukemia

CAR19PK is a research study evaluating the use of lymphodepleting chemotherapy and chimeric antigen receptor (CAR) T cell therapy, a type of cellular therapy, for the treatment of refractory and/or relapsed leukemia. For this type of thera…

Sponsor: St. Jude Children's Research Hospital
NCT ID: NCT06847269
Sites in Tennessee:
  • St. Jude Children's Research Hospital — Memphis, Tennessee
View on ClinicalTrials.gov →

Showing 25 of 39 trials with sites in Tennessee. See all leukemia trials →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-08-10